MX2014003753A - Alisporivir para el tratamiento de la infeccion por virus de la hepatitis c. - Google Patents

Alisporivir para el tratamiento de la infeccion por virus de la hepatitis c.

Info

Publication number
MX2014003753A
MX2014003753A MX2014003753A MX2014003753A MX2014003753A MX 2014003753 A MX2014003753 A MX 2014003753A MX 2014003753 A MX2014003753 A MX 2014003753A MX 2014003753 A MX2014003753 A MX 2014003753A MX 2014003753 A MX2014003753 A MX 2014003753A
Authority
MX
Mexico
Prior art keywords
alisporivir
weeks
administered
treatment
virus infection
Prior art date
Application number
MX2014003753A
Other languages
English (en)
Inventor
Claudio Avila
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2014003753A publication Critical patent/MX2014003753A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Abstract

La invención se refiere al uso de alisporivir (= Debio-025 o DEB025) en el tratamiento de un paciente afroamericano infectado con el virus de la Hepatitis C genotipo 1. El Alisporivir será administrado en una cantidad de aproximadamente 400 a aproximadamente 600 mg dos veces al día, preferiblemente en combinación con otros agentes antivirales. En una modalidad preferida, se administra el siguiente régimen de dosificación: interferón alfa 2a pegilado (PEGASYS(r)) a una dosis de 180 ug por subcutáneamente una vez a la semana durante 24 o 48 semanas en combinación con ribavirina (RBV o COPEGUS) administrada en una dosificación oral de 800/1200 mg al día (con base en el peso) durante 24 o 48 semanas y 400 mg de alisporivir (DEB025) oralmente dos veces al día durante 24 o 48 semanas.
MX2014003753A 2011-09-27 2012-09-25 Alisporivir para el tratamiento de la infeccion por virus de la hepatitis c. MX2014003753A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161539662P 2011-09-27 2011-09-27
PCT/EP2012/068896 WO2013045460A1 (en) 2011-09-27 2012-09-25 Alisporivr for treatment of hepatis c virus infection

Publications (1)

Publication Number Publication Date
MX2014003753A true MX2014003753A (es) 2014-05-01

Family

ID=46924444

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014003753A MX2014003753A (es) 2011-09-27 2012-09-25 Alisporivir para el tratamiento de la infeccion por virus de la hepatitis c.

Country Status (11)

Country Link
US (2) US20140228281A1 (es)
EP (1) EP2760461A1 (es)
JP (1) JP2014528947A (es)
KR (1) KR20140070565A (es)
CN (1) CN103826654A (es)
AU (1) AU2012314517A1 (es)
BR (1) BR112014007247A2 (es)
CA (1) CA2850052A1 (es)
MX (1) MX2014003753A (es)
RU (1) RU2014116988A (es)
WO (1) WO2013045460A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015136455A1 (en) * 2014-03-13 2015-09-17 Novartis Ag New treatments of hepatitis c virus infection

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
HUT75533A (en) 1993-11-10 1997-05-28 Schering Corp Improved interferon polymer conjugates
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6924270B2 (en) * 2000-04-20 2005-08-02 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
DK1793844T3 (da) * 2004-10-01 2011-03-21 Debiopharm Sa Anvendelse af [D-MeAla]3-[EtVal]4-cyklosporin til behandling af hepatitis C-infektion
EP1830871A1 (en) 2004-12-23 2007-09-12 Novartis AG Compositions for hcv treatment
US20100122054A1 (en) * 2008-11-12 2010-05-13 Sandisk Il Ltd. Copy safe storage
CN102753173A (zh) * 2009-12-18 2012-10-24 贝林格尔.英格海姆国际有限公司 Hcv组合疗法
BR112013013166A2 (pt) * 2010-11-30 2016-09-06 Novartis Ag tratamentos da infecção pelo vírus da hepatite c
RU2013148539A (ru) * 2011-03-31 2015-05-10 Новартис Аг Алиспоривир для лечения инфекции вируса гепатита с

Also Published As

Publication number Publication date
AU2012314517A1 (en) 2014-04-17
US20140228281A1 (en) 2014-08-14
EP2760461A1 (en) 2014-08-06
US20150328280A1 (en) 2015-11-19
CN103826654A (zh) 2014-05-28
WO2013045460A1 (en) 2013-04-04
CA2850052A1 (en) 2013-04-04
JP2014528947A (ja) 2014-10-30
KR20140070565A (ko) 2014-06-10
BR112014007247A2 (pt) 2017-03-28
RU2014116988A (ru) 2015-11-10

Similar Documents

Publication Publication Date Title
EP2583677A3 (en) Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon.
NZ631155A (en) Combination of two antivirals for treating hepatitis c
PH12014502847A1 (en) Combination treatment (eg with abt-072-333) of daas for use in treating hcv
RU2012136824A (ru) Способы лечения вирусной инфекции гепатита с
JP2014530874A5 (es)
RU2007105354A (ru) Применение комбинации циклоспорина и пэгилированного интерферона для лечения гепатита с (hcv)
MX2015012536A (es) Combinacion de agentes antivirales de accion directa y ribavirina para el tratamiento de pacientes con vhc.
RU2013148779A (ru) Лечение инфекции вируса гепатита в по отдельности или в комбинации с вирусом гепатита дельта и родственных заболеваний печени
RU2011127080A (ru) Производное циклоспорина для применения в лечении заражения вирусом гепатита с и вич
NZ598465A (en) Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
NZ588655A (en) Treatment of hepatitis c virus infections with telaprevir (vx-950) in patients non-responsive to treatment with pegylated interfer0n-alpha-2a/2b and ribavirin
MX2013000242A (es) Tratamiento de enfermedades relacionadas con el virus de hepatitis c que usa hidroxicloroquina o una combinacion de hidroxicloroquina y un agente antiviral.
RU2010153688A (ru) Режим дозирования телапревира
MX2014003753A (es) Alisporivir para el tratamiento de la infeccion por virus de la hepatitis c.
RU2013129824A (ru) Новое лечение инфекции вируса гепатита с
RU2013148539A (ru) Алиспоривир для лечения инфекции вируса гепатита с
NZ587372A (en) Treatment of bacterial, protozoan infections and cancer with a mixture of at least three different human interferon alpha proteins
RU2012109938A (ru) Способ лечения вирусного гепатита с
Kaya Peginterferon-α-2a/ribavirin/telaprevir
Znoiko Peginterferon/ribavirin
RU2013150344A (ru) Лечение инфекции вируса гепатита алисповиром
RU2011104926A (ru) Способ профилактики или лечения клещевого энцефалита
Kravchenko et al. Effect of HIV infection‐related factors on SVR rate in HCV treatment in HIV‐infected patients
Li Peginterferon-alfa-2a
Curran Interferons/ribavirin/telaprevir